Alembic Pharmaceuticals has reported a 16% revenue growth to Rs. 1,910 Cr and a 20% increase in PAT to Rs. 185 Cr for Q2 FY26, with R&D investment around 10% of revenue, while acquiring Utility Therapeutics for branded drug ventures in the US.
AI Assistant
Alembic Pharmaceuticals Ltd
2025
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.